Solius designs and sells UVB light-therapy devices, most recently launching the Solius Pro, a wall-mounted device priced at $2,995 that delivers targeted 293-nanometer UVB in a single weekly session of under five minutes. The device uses a patent-pending skin-scanning system to calculate personalized UVB doses and is controlled via a smartphone app. The Solius Pro is FDA-cleared as a Class II medical device under product code SGZ for stimulating vitamin D production in people 22 and older. Founded in 2013, Solius originally developed large walk-in light-therapy kiosks deployed in clinics and pharmacies before refocusing on a smaller at-home product. Chris Kiple became CEO in 2023 and led a recapitalization and product redesign effort. The company has just over 20 employees and has recorded more than 1,000 pre-orders ahead of shipping, which is expected to begin in July.

Total raised

$23M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2026